Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

15.61
-0.1850-1.17%
Volume:58.02K
Turnover:909.75K
Market Cap:1.11B
PE:-4.69
High:15.82
Open:15.82
Low:15.52
Close:15.79
52wk High:62.75
52wk Low:5.95
Shares:71.37M
Float Shares:40.42M
Volume Ratio:0.88
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3285
EPS(LYR):-1.8918
ROE:-54.33%
ROA:-30.72%
PB:3.86
PE(LYR):-8.25

Loading ...

Press Release: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Dow Jones
·
Feb 10

Analysts Are Bullish on Top Healthcare Stocks: Hims & Hers Health (HIMS), MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Feb 10

MoonLake Immunotherap Price Target Maintained With a $24.00/Share by BTIG

Dow Jones
·
Feb 10

MoonLake Immunotherap Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 03

FDA Grants Fast Track Designation to MoonLake’s Sonelokimab for Palmoplantar Pustulosis

Reuters
·
Feb 02

Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Moderna (MRNA)

TIPRANKS
·
Jan 20

MoonLake Immunotherapeutics (MLTX) Is Down 7.4% After FDA Clears HS BLA Path Using Existing Trials

Simply Wall St.
·
Jan 19

MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs

TIPRANKS
·
Jan 15

MoonLake Immunotherapeutics Shares Rise After BTIG Upgrade

MT Newswires Live
·
Jan 10

BTIG Research Upgrades MoonLake Immunotherapeutics to Buy From Neutral, $24 Price Target

MT Newswires Live
·
Jan 09

MoonLake Immunotherapeutics : Btig Raises to Buy From Neutral

THOMSON REUTERS
·
Jan 09

MoonLake price target raised to $32 from $26 at H.C. Wainwright

TIPRANKS
·
Jan 09

MoonLake Immunotherap Raised to Buy From Neutral by BTIG

Dow Jones
·
Jan 09

MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating

TIPRANKS
·
Jan 09

BUZZ-U.S. STOCKS ON THE MOVE-DoorDash, Duolingo, Gap

Reuters
·
Jan 09

MoonLake Immunotherapeutics Up Nearly 26%, on Pace for Largest Percent Increase Since June 2023 -- Data Talk

Dow Jones
·
Jan 09

MoonLake (MLTX): De-Risked HS Pathway and Multi-Indication Pipeline Support Attractive Risk/Reward and Buy Rating

TIPRANKS
·
Jan 08

MoonLake Immunotherapeutics Shares Soar 32..9% as US FDA Clears Path for Skin Disease Drug Filing

THOMSON REUTERS
·
Jan 08

BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, Nike

Reuters
·
Jan 08

Biotech Stock MoonLake Surges 33% After Announcing Positive Outcome From Type B Meeting With U.S. FDA

Reuters
·
Jan 08